Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
TBC halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Withdrawn
Kineret anakinra Still's disease Withdrawn
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
TBC daprodustat Anemia due to chronic kidney disease Withdrawn
TBC ferumoxytol Iron deficiency anemia Withdrawn
Adcetris brentuximab vedotin Hodgkin lymphoma Withdrawn
Winlevi clascoterone Acne vulgaris Withdrawn
Tysabri natalizumab Multiple Sclerosis, relapsing-remitting Withdrawn
Aduhelm aducanumab Alzheimer’s disease Withdrawn